AMLX vs ECL
Amylyx Pharmaceuticals Inc (AMLX) versus Ecolab Inc (ECL) — a side-by-side from cached financials, not a winner call.
Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company listed on US.
Ecolab Inc (ECL) is a specialty chemicals company listed on US.
Latest reported AMLX revenue for 2024-12-31 was $87.4M. Net income was -$301.7M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AMLX currently screens at market cap $561.6M.
Latest reported ECL revenue for 2024-12-31 was $4.01B. Net income was $2.13B. Revenue was up 0.2% from 2024-09-30 to 2024-12-31. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
AMLX currently screens at market cap $561.6M. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
Not investment advice. Open the AMLX and ECL stock pages for the full models.
Not investment advice.